MARKET

LUMO

LUMO

Lumos Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.78
+0.02
+0.26%
Closed 16:00 04/03 EDT
OPEN
7.77
PREV CLOSE
7.76
HIGH
7.97
LOW
7.20
VOLUME
8.89K
TURNOVER
--
52 WEEK HIGH
32.40
52 WEEK LOW
6.74
MARKET CAP
64.22M
P/E (TTM)
-0.0833
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LUMO stock price target is 36.00 with a high estimate of 36.00 and a low estimate of 36.00.

EPS

LUMO News

More
  • Lumos Pharma Promotes John C. McKew, PhD to Chief Operating Officer and Chief Scientific Officer
  • GlobeNewswire · 1d ago
  • Think twice before investing in biotech companies working on coronavirus treatments the odds of picking a winner are low
  • MarketWatch · 03/18 13:45
  • NewLink shareholders back Lumos merger
  • Seeking Alpha - Article · 03/18 12:16
  • Newlink Genetics Stockholders Approve Merger With Lumos Pharma
  • Reuters · 03/18 12:03

Industry

Biotechnology & Medical Research
-0.74%
Pharmaceuticals & Medical Research
-0.56%

Hot Stocks

Symbol
Price
%Change

About LUMO

Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.
More

Webull offers kinds of Lumos Pharma Inc stock information, including NASDAQ:LUMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUMO stock news, and many more online research tools to help you make informed decisions.